medline.ch Onkologie Urologische Tumoren

	From hematuria warning to precision immunotherapy: an AI-assisted cross-platform analysis of bladder cancer information on social media. Front Med (Lausanne) Han P, Yang X, Li Q, Lu P, Wang P, Deng Z, Gui Z, Zong Y, Liu M. PMID: 42760942 [PubMed]
	Clinical efficacy of AI-navigated transperineal MRI-TRUS fusion biopsy for prostate cancer diagnosis: A retrospective cohort study. Medicine (Baltimore) Chen J, Xu Q, Li C, Zhang J. PMID: 42760671 [PubMed - indexed for MEDLINE]
	Single-cell transcriptomics combined with Mendelian randomization reveals the pivotal role of WDR83OS in clear cell renal cell carcinoma: An observational and bioinformatic study. Medicine (Baltimore) Xiao L, Yusan A, Cao Y, Yue F, Feng J, Wu H, Sun L, Qiu J, Xiao Y, Zhang S. PMID: 42760660 [PubMed - indexed for MEDLINE]
	Satisfaction with treatment decision-making and long-term experiences of life-prolonging treatments for metastatic castration-resistant prostate cancer. BMC Palliat Care Routier Cañigueral P, Wennman-Larsen A, Doveson S, Rönningås U, Holm M. PMID: 42760521 [PubMed - indexed for MEDLINE]
	Current status and future directions of AI in prostate cancer detection on MRI: a special report from the ESUR prostate MRI working group authors. Eur Radiol Cuocolo R, Ponsiglione A, Agrotis G, Barrett T, Brembilla G, Caglic I, Fali, Hamm CA, Messina E, Penzkofer T, Renard-Penna R, Rouvière O, Russo L, Sala E, Uhlig J, Padhani AR, de Rooij M, ESUR Prostate MRI Working Group. PMID: 42760428 [PubMed - as supplied by publisher]
	Assessment of Bone Metastases, Skeletal-Related Events and Bone-Targeting Agents in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Systemic Therapy (Meet-URO 33 Study Subanalysis). Clin Genitourin Cancer Valsecchi AA, Rebuzzi SE, Cursano MC, Pantano F, Berardi R, Bimbatti D, Bonomi L, Bozza G, Bronte E, Buti S, Carella C, Cavo A, Cocorocchio E, Volta AD, Deppieri FM, Di Marco A, Di Napoli M, Fanelli M, Fantinel E, Dri A, Filippi R, Fornarini G, Galli L, Guida A, Icardi M, La Russa F, Lolli C, Lombardo L, Maines F, Maiorano BA, Masini C, Messina C, Nasso C, Ortega C, Pierantoni F, Procopio G, Scagliarini S, Signori A, Sorarù M, Tondulli L, Verzoni E, Vignani F, Vitale MG, Zai S, Zucali PA, De Giorgi U, Santini D, Di Maio M. PMID: 42760246 [PubMed - as supplied by publisher]
	Is This the End of the Cisplatin Eligibility Era in Muscle-invasive Bladder Cancer? Letter in reference to: Matthew D. Galsky, BegoÃ±a P. Valderrama, Marco Maruzzo, et al. Enfortumab vedotin and pembrolizumab in cisplatin-eligible bladder cancer. N Engl J Med 2026;395:338-48. doi:10.1056/NEJMoa2601486; and Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 2011;12:211-214. doi:10.1016/S1470-2045(10)70275-8. Eur Urol Giannatempo P, Cerbone L, Calabrò F. PMID: 42760245 [PubMed - as supplied by publisher]
	Can early (68)Ga-PSMA-11 PET/CT predict 6-month disease control in patients receiving first-line systemic therapy for metastatic clear-cell renal cell carcinoma? Protocol for the multicentre prospective phase II PSMA-RENAL study in Belgium. BMJ Open Seront E, Lhommel R, Van Maanen A, Pasoglou V, Gizzi M, Grisay G, Tombal B. PMID: 42760067 [PubMed - indexed for MEDLINE]
	The PART randomised trial protocol: Partial Ablation versus Radical Treatment for prostate cancer. BJU Int Bryant RJ, Leslie T, Laniado M, Sharma A, Grey A, Withington J, Blick C, Streeter E, Kotwal S, Hulson O, Cross W, Good DW, Omer A, Shah TT, Bedi N, Stroman L, Moore C, Sooriakumaran P, Ahmed HU, Brewster SF, Barber VS, Hewitt A, Calvert C, Scaife J, Shepherd D, Landeiro F, Wolstenholme J, Camilleri P, Verrill C, Lovell S, Pirkl M, Gleeson F, Williams R, Cook J, Holt CR, Hill M, Cook J, Radford J, Marian IR, Macpherson R, Elliott D, Donovan JL, Hamdy FC. PMID: 42760023 [PubMed - as supplied by publisher]
	Plasma cfDNA fragmentomics enables non-invasive detection and preoperative risk stratification of bladder cancer in a multicenter study. Cancer Lett Liu K, Bao H, Li G, Ran W, Yang P, Zhang Z, Li W, Li N, Ren M, Ding T, He P, Yang S, Hong X, Wang K, Xing X. PMID: 42759922 [PubMed - as supplied by publisher]
	Efficacy and safety analysis of disitamab vedotin combined with immunotherapy as neoadjuvant treatment to promote conversion to bladder preservation in bladder cancer: A retrospective comparative study with the GC combined with immunotherapy regimen. Urol Oncol Li J, Chen K, Zhang S, Shen Y, Chen Z, Xu D, Liu H, Shen H. PMID: 42759308 [PubMed - as supplied by publisher]
	Diagnostic value of CEUS-VI-RADS for predicting muscle invasion in bladder cancer: Validation of the scoring system and introduction of tumor-bladder wall contact length as a supplementary quantitative metric. Urol Oncol Qu W, Zhu J, Yang Y, Nie F. PMID: 42759306 [PubMed - as supplied by publisher]
	(18)F-labeled prostate-specific membrane antigen positron emission tomography/computed tomography vs. magnetic resonance imaging in diagnosis of prostate cancer A meta-analysis. Can Urol Assoc J Feng H, Su Y, Lu F. PMID: 42758927 [PubMed]
	Comparison of inflammation-based biomarkers in metastatic testicular cancer at initial diagnosis. Can Urol Assoc J Hacibey I, Ozer E, Demiriz B, Nisli O, Akalin B, Ozdemir H, Canat HL. PMID: 42758921 [PubMed]
	Quantitative MRI for World Health Organisation/International Society of Urological Pathology Grading of Renal Cell Carcinoma: a systematic review and diagnostic meta-analysis. Eur Radiol Kiani I, Fujiwara M, Mohammadzadeh S, Pourakbar N, Kwee TC, Masuyama S, Nissan N, Woo S, Yoshida S, Arita Y. PMID: 42758284 [PubMed - as supplied by publisher]
	Impact of resection bed management on postoperative outcomes after Robot-Assisted Partial Nephrectomy : a retrospective French Nationwide Study (UroCCR 215). World J Urol Paillusson D, Margue G, Champy C, Doumerc N, Bigot P, Bruyere F, Paparel P, Surlemont L, Olivier J, Durand M, Branger N, Waeckel T, Fontenil A, Vallee M, Ouzaid I, Patard JJ, Guillotreau J, Panthier F, Belas O, Boissier R, Taha F, Letang N, Parier B, Lang H, Dameron C, Verhoest G, Sarrazin C, Bernhard JC, Bobet S, Karakachoff M, de Vergie S. PMID: 42758231 [PubMed - indexed for MEDLINE]
	MR Virtual Cytometry for Zone-specific Prostate Cancer Characterization with Histologic and Molecular Validation. Radiol Imaging Cancer Lu J, Cheng H, Li H, Liu K, Xu H, Ba R, Liu M, Zhang W, Zhu H, Chen M, Li C, Wu D. PMID: 42757967 [PubMed - indexed for MEDLINE]
	MH-Penile-002: a phase II, prospective, single-arm trial of neoadjuvant anti-EGFR antibody-drug conjugate plus PD-1 inhibitor in penile cancer with challenging penile preservation or regional lymph node metastasis. Future Oncol Wang JY, Shao YX, Yang LL, Li HS, Liu JQ, Liu RZ, Zhang S, Li X, Liu JY. PMID: 42757773 [PubMed - as supplied by publisher]
	Eomesodermin in renal cell carcinoma: Epigenetic and immune crosstalk driving tumor progression (Review). Int J Oncol Che Z, Huang D, Lin J, Wang X, Feng R, Che X, Wang Y. PMID: 42757465 [PubMed - indexed for MEDLINE]
	Bridging the Resolution Gap in Recurrent Prostate Cancer Imaging: Quantum Dots as PSMA-Targeted Optical Probes. ACS Omega Gidiya Y, Chaudhary J, Biswas A, Liao M, Ramaroson M, Kamei KI. PMID: 42757093 [PubMed]

Artikel 1 - 20 / 181573

Seite 1 von 9079

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung